Authors: Markku Tykkylainen*, University of Eastern Finland, Aapeli Leminen, University of Eastern Finland, Maija Toivakka, University of Eastern Finland, Teppo Repo, University of Eastern Finland, Tiina Laatikainen, University of Eastern Finland
Topics: Medical and Health Geography, Geographic Information Science and Systems, Planning Geography
Keywords: geospatial health, health geograpy, type 2 diabetes, cardiovascular diseases, health care planning, Finland
Session Type: Paper
Start / End Time: 8:00 AM / 9:40 AM
Room: Balcony N, Marriott, River Tower Elevators, 4th Floor
Presentation File: No File Uploaded
This research project analyses primary health care processes, their quality and costs individually and at different geographical levels among diabetes and cardiovascular disease patients in a Finnish health care region, equal in size of New Jersey. The aim of the project is to assess the cost-effectiveness of different accessibility solutions for health care and the influence of the areal and individual SES factors, life-styles and physical and virtual accessibility on treatment outcomes. The project develops a generic model which helps the management of CVD and T2DM care to be improved in Finnish health care regions.
Our data consists of type 2 diabetes patients (n=10204) and patients with acute coronary events (n=2556) since 2010. We apply geocoded register data and national grid-based and postcode area-level spatial databases and the Digiroad database for analysis and for the optimization of care cost-efficiently. The first generic model has been developed for searching for optimal care solutions in primary health care. The results show that geographical accessibility doesn’t impact on the use of health care although the life style and SES factors impact on the predisposition and prevalence of T2DM and CVD and the outcomes of care. These factors and their implications are varying geospatially and clustered and thus challenging to target the supply of health services geographically. During the next three years, we will investigate and model the cost and outcome benefits of mobile and telehealth technologies in monitoring and management of T2DM and CVD patients.